Aligos Therapeutics Announces Reverse Stock Split

Core Viewpoint - Aligos Therapeutics, Inc. is implementing a 1-for-25 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00, effective August 19, 2024 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 25 shares of common stock into one share, maintaining the par value at $0.0001 per share [2]. - No fractional shares will be issued; stockholders will receive cash payments for any fractional shares [2]. - The reverse stock split was approved by stockholders on June 27, 2024, and subsequently by the Board of Directors [3]. Group 2: Company Overview - Aligos Therapeutics is a clinical stage biopharmaceutical company founded in 2018, focusing on liver and viral diseases [5]. - The company aims to develop best-in-class therapeutics for conditions like metabolic dysfunction-associated steatohepatitis (MASH) and high unmet medical need viruses such as hepatitis B and coronaviruses [5].